Daniel Nomura Explained

Daniel K. Nomura
Fields:Chemical Biology, Chemistry, Molecular and Cell Biology, Drug Discovery, Cancer Biology
Spouses:)-->
Alma Mater:University of California, Berkeley;University of California, Berkeley
Workplaces:
  • Innovative Genomics Institute
  • Novartis-Berkeley Translational Chemical Biology Institute
Birth Date:July 10th, 1981

Daniel K. Nomura is an American chemical biologist and Professor of Chemical Biology and Molecular Therapeutics at the University of California, Berkeley, in the Departments of Chemistry and Molecular & Cell Biology. His work employs chemoproteomic approaches to develop small molecule therapeutics and therapeutic modalities against traditionally "undruggable" proteins.[1]

He is a member of the scientific advisory committee of the Mark Foundation for Cancer Research, a foundation set up by billionaire Alexander Knaster which funds early-stage cancer research. [2] He is also an Investment Advisory Partner for, an Investment Advisor for Droia Ventures, and an with The Column Group.[3]

Research and education

Nomura received his BA in Molecular and Cell Biology in 2003 and PhD in Molecular Toxicology in 2008 from UC Berkeley, studying under the mentorship of John Casida. He went on to perform his postdoctoral research with Ben Cravatt at Scripps Research in La Jolla, California. There he discovered a role for monoacylglycerol lipase in generating oncogenic signaling lipids that promote cancer[4] and in proinflammatory cascades that impact neurodegenerative disorders.[5] In 2011, Nomura started his independent research group at UC Berkeley. His work focuses on implementing chemoproteomic platforms to develop small molecule therapeutics against traditionally "undruggable" proteins. These approaches have led to the discovery of novel inhibitors and new ligands that expand the scope of proteolysis targeting chimeras (PROTACS),[6] which are bifunctional molecules that harness the cells ubiquitin-proteasome system to degrade targets of interest. Notable recent discoveries include an inhibitor of mTORC1,[7] a molecular glue between UBR7 and p53 that activates p53 tumor suppressor activity,[8] a covalent inhibitor against MYC,[9] novel covalent recruiters against E3 ubiquitin ligases such as RNF114, RNF4, and FEM1B for targeted protein degradation applications,[10] [11] [12] the Deubiquitinase Targeting Chimera (DUBTAC) platform for targeted protein stabilization,[13] and a chemical rational design strategy for developing molecular glue degraders.[14] In 2017, Nomura became the Director of the Novartis-Berkeley Translational Chemical Biology Institute,[15] [16] which aims to develop chemical technologies and therapeutics against undruggable targets. Nomura is also co-founder of Frontier Medicines and Vicinitas Therapeutics.[17] [18]

Awards

Notes and References

  1. Web site: Novartis and Berkeley researchers team up to tackle the industry's toughest drug targets. 2020-08-27. Chemical & Engineering News. en.
  2. Web site: Daniel Nomura, PhD. 26 January 2021.
  3. Web site: Droia Ventures – Investing in Impact – Life Science . 2022-11-21 . Droia Ventures – Investing in Impact . en-US.
  4. Nomura. Daniel K.. Long. Jonathan Z.. Niessen. Sherry. Hoover. Heather S.. Ng. Shu-Wing. Cravatt. Benjamin F.. 2010-01-08. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 140. 1. 49–61. 10.1016/j.cell.2009.11.027. 1097-4172. 2885975. 20079333.
  5. Nomura. Daniel K.. Morrison. Bradley E.. Blankman. Jacqueline L.. Long. Jonathan Z.. Kinsey. Steven G.. Marcondes. Maria Cecilia G.. Ward. Anna M.. Hahn. Yun Kyung. Lichtman. Aron H.. Conti. Bruno. Cravatt. Benjamin F.. 2011-11-11. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 334. 6057. 809–813. 10.1126/science.1209200. 1095-9203. 3249428. 22021672. 2011Sci...334..809N.
  6. Web site: Jarvis. Lisa M.. Targeted protein degraders are redefining how small molecules look and act. 2020-08-27. Chemical & Engineering News. en.
  7. Chung. Clive Yik-Sham. Shin. Hijai R.. Berdan. Charles A.. Ford. Breanna. Ward. Carl C.. Olzmann. James A.. Zoncu. Roberto. Nomura. Daniel K.. August 2019. Covalent targeting of the vacuolar H+-ATPase activates autophagy via mTORC1 inhibition. Nature Chemical Biology. 15. 8. 776–785. 10.1038/s41589-019-0308-4. 1552-4469. 6641988. 31285595.
  8. Isobe. Yosuke. Okumura. Mikiko. McGregor. Lynn M.. Brittain. Scott M.. Jones. Michael D.. Liang. Xiaoyou. White. Ross. Forrester. William. McKenna. Jeffrey M.. Tallarico. John A.. Schirle. Markus. 2020-06-22. Manumycin polyketides act as molecular glues between UBR7 and P53. Nature Chemical Biology. 16. 11. 1189–1198. 10.1038/s41589-020-0557-2. 1552-4469. 32572277. 7572527. 219976949.
  9. Boike . Lydia . Cioffi . Alexander G. . Majewski . Felix C. . Co . Jennifer . Henning . Nathaniel J. . Jones . Michael D. . Liu . Gang . McKenna . Jeffrey M. . Tallarico . John A. . Schirle . Markus . Nomura . Daniel K. . 2021-01-21 . Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC . Cell Chemical Biology . en . 28 . 1 . 4–13.e17 . 10.1016/j.chembiol.2020.09.001 . 32966806 . 7854864 . 221888024 . 2451-9456. free .
  10. Spradlin. Jessica N.. Hu. Xirui. Ward. Carl C.. Brittain. Scott M.. Jones. Michael D.. Ou. Lisha. To. Milton. Proudfoot. Andrew. Ornelas. Elizabeth. Woldegiorgis. Mikias. Olzmann. James A.. July 2019. Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. Nature Chemical Biology. 15. 7. 747–755. 10.1038/s41589-019-0304-8. 1552-4469. 6592714. 31209351.
  11. Ward . Carl C. . Kleinman . Jordan I. . Brittain . Scott M. . Lee . Patrick S. . Chung . Clive Yik Sham . Kim . Kenneth . Petri . Yana . Thomas . Jason R. . Tallarico . John A. . McKenna . Jeffrey M. . Schirle . Markus . Nomura . Daniel K. . 2019-11-15 . Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications . ACS Chemical Biology . en . 14 . 11 . 2430–2440 . 10.1021/acschembio.8b01083 . 1554-8929 . 7422721 . 31059647.
  12. Henning . Nathaniel J. . Manford . Andrew G. . Spradlin . Jessica N. . Brittain . Scott M. . Zhang . Erika . McKenna . Jeffrey M. . Tallarico . John A. . Schirle . Markus . Rape . Michael . Nomura . Daniel K. . 2022-01-19 . Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications . Journal of the American Chemical Society . en . 144 . 2 . 701–708 . 10.1021/jacs.1c03980 . 0002-7863 . 8928484 . 34994556.
  13. Henning . Nathaniel J. . Boike . Lydia . Spradlin . Jessica N. . Ward . Carl C. . Liu . Gang . Zhang . Erika . Belcher . Bridget P. . Brittain . Scott M. . Hesse . Matthew J. . Dovala . Dustin . McGregor . Lynn M. . Valdez Misiolek . Rachel . Plasschaert . Lindsey W. . Rowlands . David J. . Wang . Feng . April 2022 . Deubiquitinase-targeting chimeras for targeted protein stabilization . Nature Chemical Biology . en . 18 . 4 . 412–421 . 10.1038/s41589-022-00971-2 . 35210618 . 233745282 . 1552-4469. free . 10125259 .
  14. Toriki . Ethan S. . Papatzimas . James W. . Nishikawa . Kaila . Dovala . Dustin . McGregor . Lynn M. . Hesse . Matthew J. . McKenna . Jeffrey M. . Tallarico . John A. . Schirle . Markus . Nomura . Daniel K. . 2022-11-04 . Rational Chemical Design of Molecular Glue Degraders . en . 2022.11.04.512693 . 10.1101/2022.11.04.512693. 253371370 .
  15. News: Novartis, UC Berkeley join forces for 'undruggable' targets. 2020-08-27. Fierce Biotech. 28 September 2017 . en.
  16. Web site: Staff. Hyunkyu Michael Lee . 2017-10-02. UC Berkeley researchers partners with Novartis to develop new cures. 2020-08-28. The Daily Californian. en-US.
  17. Web site: C&EN's 2019 10 Start-Ups to Watch. 2020-08-27. Chemical & Engineering News. en.
  18. News: 2022-07-28 . Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins . en . Bloomberg.com . 2022-11-21.
  19. Web site: Daniel Nomura, PhD. 26 January 2021.
  20. Web site: Daniel Nomura receives ASPIRE Award from the Mark Foundation | College of Chemistry.
  21. Web site: 2022-11-02 . NCI Outstanding Investigator Award Recipients - NCI . 2022-12-04 . www.cancer.gov . en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Daniel Nomura".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.